Biohackers, chew this.
Anti-aging affairs have all tried-including taking certain medicines out of labels in the hope that they will lead to longer and healthier life.
A new study from Germany provides new evidence that this approach can be valid. Researchers at the Max Planck Institute for Aging Biology found that a combination of two cancer drugs lasted the life of mice by about 30%.
But the buyer be careful. One of the drugs, Rapamyc, has sparked controversy over its security and effectiveness in humans. Bukhacking Buff Bryan Johnson, 47, even agreed to throw it out of his regime.
Rapamycin is an immunosuppressant used to prevent organs from rejection in patients with transplantation.
The pill was found in the new study to increase mouse life by 15% to 20% on its own.
Rapamycin impedes the MTOR path, which regulates major body functions such as protein synthesis, cell growth and cleaning “mummy” cells that do not function properly but refuse to die.
Because suppresses the immune system, a major weakness of Rapamycin is that it increases the risk of infections.
Other potential side effects include elevated levels of cholesterol and triglycerides in the blood, gastrointestinal problems, skin issues, headaches, fatigue and drug interactions.
Johnson had experimented with various doses of drugs over five years before stopping to take it in September.
“Despite the extraordinary potential of pre-clinical evidence, my team and I concluded that the benefits of eternal dosage of Rapamycin do not justify major side effects (soft tissue intermittent infections, lipid abnormalities, glucose heights and increased heartbeat),” Johnson wrote.
Rapamyc, along with Trametinib, worked miracles in the new study.
Trametinib is used to treat several types of melanoma and low -scale glioma, among other cancers. It interferes with signals that show cancer cells multiply.
Trametinib extended mouse life with 5% to 10% alone – and it was even better with Rapamyc.
“Tramatinib, especially in combination with Rapamyci, is a good candidate to be tested in clinical trials as geroprotector,” said study author Sebastian Grãnke.
“Hopefully our results will be taken from others and tested in humans. Our focus is on optimizing the use of trams in animal models.”
The one-two work of Rapamycin and Trametinib influenced the expression of the gene unlike each drug in itself.
Researchers found lower amounts of harmful inflammation in the tissues and the brain, and the cancer did not develop so fast.
The findings were published this week in the journal Nature Aging.
“While we do not expect an extension similar to human life expectancy as we found in rats, we hope that the medicines we are investigating can help people stay healthy and without illness for more late in life,” the author said Linda Partridge.
“Further research in people in the coming years will help us to clarify how these medicines can be useful to people, and who may be able to benefit.”
#medicines #rats #live #longer #Bryan #Johnson #warned #downsides
Image Source : nypost.com